Physician profile
Ryan T Jones
NPI 1225411705
$9,393.62
in general payments reported to CMS, 2019-2025
42 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 84% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $822 · 2021: $1,286 · 2022: $1,491 · 2023: $1,621 · 2024: $1,672 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,798 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,797.98 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,058.04 | 2019-2025 | |
| Janssen Biotech, INC. | $1,190.08 | 2020-2025 | Tremfya, Remicade, Simponi |
| Novartis Pharmaceuticals Corporation | $684.93 | 2019-2025 | |
| Amgen INC. | $514.37 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $500.79 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $443.48 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $411.78 | 2019-2025 | Dupixent |
| Genzyme Corporation | $402.03 | 2020-2025 | |
| Incyte Corporation | $350.68 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $344.71 | 2022-2024 | Sotyktu |
| Ucb, INC. | $337.11 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $190.19 | 2023-2024 | Vtama |
| Leo Pharma INC. | $189.33 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $159.69 | 2019-2024 | Siliq |
| Arcutis Biotherapeutics, INC. | $159.07 | 2023-2025 | Zoryve |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $138.67 | 2023-2024 | Idacio |
| Genentech USA, INC. | $128.33 | 2021-2024 | Erivedge, Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.56 | 2023-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $99.30 | 2020-2021 | |
| Celgene Corporation | $83.06 | 2019 | |
| Pfizer INC. | $80.79 | 2019-2025 | |
| Organogenesis INC. | $76.45 | 2021-2024 | Puraply, Cygnus Dual |
| Journey Medical Corporation | $74.55 | 2022-2023 | |
| Galderma Laboratories, L.P. | $70.23 | 2019-2024 | Epsolay, Aklief, Oracea |
| Mayne Pharma Commercial LLC | $55.97 | 2019-2021 | |
| Allergan, INC. | $52.03 | 2019-2021 | |
| Kyowa Kirin, INC. | $49.39 | 2022-2025 | Poteligeo |
| Mimedx Group, INC. | $48.19 | 2024-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $46.04 | 2019-2023 | Valchlor |
| Epi Health, LLC | $44.60 | 2019-2020 | |
| Revance Therapeutics, INC. | $44.32 | 2024 | Daxxify |
| Kerecis Limited | $41.13 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Almirall LLC | $36.68 | 2019-2020 | |
| Biofrontera INC. | $36.27 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Prugen, INC. Pharmaceuticals | $30.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $20.31 | 2023 | |
| Organon LLC | $20.05 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $19.37 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.91 | 2021 | |
| Lnhc, INC | $15.69 | 2025 | Zelsuvmi |
| Dermira, INC. | $12.92 | 2020 | |
| Melinta Therapeutics, LLC | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.